Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin and interferon alfa-2a for severe fever with thrombocytopenia syndrome
ChiCTR-IPR-15006575Phase 4Recruiting
- Sponsor
- Beijing Institute of Microbiology and Epidemiology
- Start
- Apr 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ribavirin and interferon alfa-2a in severe fever with thrombocytopenia syndrome (SFTS) (4 arms), sponsored by Beijing Institute of Microbiology and Epidemiology. Primary endpoint: Case fatality rate of severe fever with thrombocytopenia syndrome. Started Apr 2015; status: recruiting.
02
Drugs
ribavirininterferon alfa-2a
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)
Beyond the preview
Go deeper on ChiCTR-IPR-15006575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006575.